Retatrutide and Body Composition: Glucagon + Muscle

Body composition -- the ratio of fat to lean tissue in your body -- matters far more than the number on the scale. Two people at 180 pounds can have wildly different health profiles depending on how much of that weight is muscle versus fat. This is why the body composition effects of weight loss medications deserve as much attention as the total pounds lost.

Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) demonstrated 24% average weight loss at the highest dose, the largest reduction ever seen with a pharmaceutical intervention. But what kind of weight was lost? The answer lies in how retatrutide's three receptor targets -- GLP-1, GIP, and glucagon -- each influence whether the body burns fat or breaks down muscle.

Three Receptors, Three Effects on Body Composition

Each of retatrutide's receptor targets influences body composition through distinct mechanisms. Understanding these helps explain why the triple agonist may produce superior body composition outcomes compared to single or dual agonists.

GLP-1 Receptor: The Appetite Controller

GLP-1 receptor activation reduces appetite and food intake, creating the caloric deficit that drives weight loss. From a body composition standpoint, this is a blunt instrument -- it reduces total energy intake without specifically targeting fat or muscle. The quality of weight lost during GLP-1-driven caloric deficit depends almost entirely on external factors: protein intake, exercise, and sleep.

The challenge with GLP-1-only medications like semaglutide is that appetite suppression often reduces protein intake below optimal levels, tilting the body composition balance toward muscle loss. When patients eat 1,000-1,200 calories daily and only 40-50 grams of protein, muscle protein synthesis cannot keep pace with breakdown.

GIP Receptor: The Muscle Ally

GIP receptor activation appears to favorably influence body composition through several mechanisms:

• Insulin sensitization: GIP enhances insulin's anabolic effects on muscle, promoting protein synthesis and inhibiting protein breakdown
• Adipocyte function: GIP improves fat cell health, potentially enhancing the body's ability to mobilize fat stores for energy rather than breaking down muscle
• Direct muscle effects: Emerging research identifies GIP receptors on skeletal muscle tissue, suggesting direct signaling that may support muscle preservation

The evidence from tirzepatide (GLP-1 + GIP) supports this theory. Tirzepatide produces a more favorable lean-to-fat mass loss ratio than semaglutide (GLP-1 only), with approximately 70-80% of weight lost being fat mass compared to 60-65% with semaglutide. This improvement is likely attributable to GIP's effects.

Glucagon Receptor: The Fat Burner

The glucagon receptor is retatrutide's distinguishing feature and the most intriguing component for body composition. Glucagon's effects are complex and somewhat paradoxical:

Phase 2 Body Composition Data

The Phase 2 retatrutide trial included DEXA body composition analysis in a subset of participants. While the sample size was limited and body composition was a secondary endpoint, the results provide encouraging preliminary data:

The key finding: despite producing more total weight loss than either semaglutide or tirzepatide, retatrutide did not produce proportionally more lean mass loss. The glucagon component appears to direct additional weight loss preferentially toward fat tissue, validating the theoretical advantages of triple agonism for body composition.

Visceral Fat: The Hidden Victory

Not all fat loss is created equal. Visceral fat -- the fat surrounding abdominal organs -- is far more metabolically dangerous than subcutaneous fat. It produces inflammatory cytokines, drives insulin resistance, and contributes to cardiovascular disease, fatty liver disease, and metabolic syndrome.

Glucagon receptor activation preferentially targets visceral and hepatic fat stores. This means retatrutide may produce outsized metabolic improvements relative to total weight lost, because it is selectively depleting the most harmful fat deposits. Phase 2 data showed dramatic improvements in liver fat (reductions exceeding 80% in some participants), waist circumference, and metabolic markers that correlate with visceral fat reduction.

Optimizing Body Composition on Retatrutide

While retatrutide's mechanism provides inherent body composition advantages, you can further optimize outcomes through targeted strategies:

What This Means for Patients

The body composition profile of retatrutide represents a meaningful advance over earlier GLP-1 medications. If Phase 3 data confirms the Phase 2 findings, retatrutide would offer the combination of the most weight loss and the most favorable body composition -- more total fat lost and proportionally less muscle lost than any previous pharmaceutical intervention.

For patients, this means that the fear of "losing all your muscle" on retatrutide appears overblown based on available data. The triple-agonist design seems to have solved, or at least significantly mitigated, the muscle loss concerns that plagued semaglutide. Combined with proper nutrition and resistance training, patients can expect body composition outcomes that are far more favorable than the scale alone would suggest.

To explore currently available weight loss medications and discuss body composition goals with a provider, visit our treatments page.